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Summary.The retroviral vectors based on an MFG-type backbone have superior
expression characteristics, in part, due to the presence of the retroviral chimeric
intron (MFG intron). We tested the hypothesis that inclusion of a second intron in
MFG vectors may influence packaging and/or LTR-driven transgene expression.
We constructed two MFG retroviral vectors, MFG/hFIXc and MFG/hFIXm2,
containing human factor IX (hFIX) cDNA without and with a 0.3-kb hFIX in-
tron, respectively. When tested with primary mouse myoblasts or HepG2 cells
in culture for transient expression activity, pMFG/hFIXm2 plasmid produced
two-to-three fold higher hFIX than pMFG/hFIXc. These vectors produced equiv-
alent retroviral titers from packaging cells. In transduced cells, the splicing of
the MFG intron in the retroviral transcripts occured at a similar efficiency; how-
ever, MFG/hFIXc virus gave two-fold higher hFIX expression than that of the
MFG/hFIXm2 viral infection. Analyses of MFG/hFIXm2 virion RNA and trans-
duced cell genomic DNA suggested that, although the hFIX intron containing
viral RNA are packaged, these viruses fail to integrate their transgenes into the
genome of transduced cells, suggesting a block at the reverse transcription and/or
integration steps. Similar results were also obtained with the prototype vectors,
LIXcSN and LIXm2SN, lacking the MFG intron. Together, these results suggest
that a hFIX cDNA sequence in the retroviral vectors performs better over hFIX
intron-containing minigene.
*
Recombinant retroviral vectors, derived from Moloney murine leukemia virus
(MoMLV), contain the viral Long Terminal Repeat (LTR) promoter driven trans-
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gene placed downstream of the packaging signal,9, replacing the viralgag (3′
portion),pol andenvregions [18]. The packaging signal, flanked by viral splic-
ing donor (SD) site and the transgene, has a strong secondary structure and can
interfere with the translation of the following gene. In the absence of an authentic
splicing acceptor (SA) site preceding the transgene in vectors often referred to
as LN-type (as LIXcSN), a cryptic SA is used to ensure that the9 sequence is
spliced out for efficient translation of the transgene insert sequence [2]. LIXcSN
contains human Factor IX (hFIX) cDNA under the LTR promoter and also con-
tains an SV40 promoter-neomycin-resistance gene expression unit (Fig. 1a) [30].
MFG retroviral vector contains a segment comprising of an authentic viral SA
and 5′-untranslated region of the viralenvgene preceding the transgene insert and
thus recreates the presence of a viral intron [21]. The first methionine codon of
the transgene coincides to the viralenvstart codon in these vectors. Expression of
a transgene from the MFG vectors can be 7- to 50-fold higher than that from LN
vectors [4, 13]. The ratio of spliced to unspliced vector RNA is increased by up to
four-fold for MFG vectors in transduced cells, which in part can explain higher
expression from MFG vectors [4, 11, 13]. However, the mechanism(s) responsible
for higher expression from MFG vectors is not fully understood. Other mecha-
nisms include a possible presence of internal ribosome entry segment (IRES) in
env leader [7]. It is also possible that, the chimeric viral intron allows efficient
spliceosome assembly with viral RNA in packaging cells, thus resulting in higher
levels of viral RNA for packaging and producing higher titers than the LN-type
vectors [17].
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Similar as in wild-type retrovirus, the chimeric intron in MFG vector is also
partially spliced in the packaging cells and since only the RNAs that retain the
intron are packaged, all vectors in target cells must have this intron. On the other
hand, retention of heterologous intron(s) within the transgene and placed in the
same orientation as retroviral intron have shown mixed results. Early experiments
suggested that heterologous introns included in retroviral vectors are inefficiently
(∼10%) spliced prior to packaging and may require 7–9 passages for complete
b
Fig. 1. aConstruction of retroviral vectors. Vectors used in the present studies contain 0.59-
kb LTR promoter,9 packaging signal containing region and 1.4-kb hFIXc or hFIXm2 con-
taining a 0.3-kb internally truncated first intron. LN-type vectors (LIXcSN and LIXm2SN)
or MFG vectors (MFG/hFIXc and MFG/hFIXm2) have 0.4-kb partial and 1.27-kb chimeric
viral introns, respectively. The 3′-untranslated region of vectors between transgene and LTR
is 0.14-kb in all vectors. The 1.7 kb SV-neo represents SV40 promoter and neomycin resis-
tance gene, respectively. SD and SA refer to splice donor and splice acceptor, respectively.
The expected RNA transcript sizes are shown on the right. Plasmid vectors, pMFG/hFIXc
and pMFG/hFIXm2 were constructed starting with p-416hFIXc and p-416hFIXm2, which
were previously constructed and contain 416-bp hFIX promoter and hFIX cDNA or hFIX
cDNA with a 0.3-kb intron I, respectively [14]. AnNco I linker (5′-AGCCATGGCT) was
introduced between hFIX 3′-end and poly (A) signal sequence of hFIX plasmids at the
BamHI site. Similarly, aBsmBI adapter designed to give anNco I compatible sticky end
(5′-CTAGCGTCTCACATGCAG-3′ and 5′-CGCTGCATGTGAGACG-3′) was introduced at
the 5′-end of hFIX gene. pMFG/hFIXc and pMFG/hFIXm2 expression vectors were obtained
by ligating hFIXc or hFIXm2 genes at theNcoI site of pMFG [21]. Use of theBsmBI adapter
allowed that the translational start codon corresponded to that of the viralenvwithout al-
tering the second codon of hFIX. pLIXm2SN was constructed by replacing the hFIXc of
pLIXcSN with hFIXm2 after digesting withBamHI. Retroviral vectors were prepared using
the Phoenix-A cell line [9, 12] which was grown in Dulbecco’s modified essential medium
(DMEM) supplemented with 20% fetal bovine serum (FBS) and penicillin-streptomycin at
37◦C. Cells at 60–80% confluency in 9-cm diameter dishes were transfected overnight with
24mg of retroviral plasmid DNAs. Next morning, medium was replaced with 4 ml of fresh
medium, and plates were incubated in humidified incubator at 32◦C. After 48 hours, re-
combinant retroviruses (culture supernatants) were harvested, filtered through 0.22m filters,
aliquoted and stored at−70◦C until use.b Transient expression of hFIX by myoblasts trans-
fected with expression plasmid vector DNAs. Mouse myoblasts (∼2.5×105 cells) were plated
on 6-well plates one day prior to transfections and grown in DMEM supplemented with 20%
FBS and 0.5% chicken embryo extracts (CEE) [28]. Cells were transfected next day with
1mg of plasmid DNA mixed with FuGENE6 (Roche Biochemicals) (transfection efficiency
of 5–10%) [26]. The transfection medium was replaced with fresh medium supplemented
with Vitamin K1 (10mg/ml) and BaSO4-treated FBS [27] on the following day, harvested
48 h thereafter and used for measuring hFIX by ELISA [14] as previously described. At the
end of experiment, the total myoblast cell number was∼4×106 per well. Results shown
from three independent experiments normalized to 106 cells and 24 h are shown (standard
deviation,<5%). Similarly, HepG2 cells (3×105 cells plated on 6-cm dishes one day prior to
transfection) were transfected with 8mg of plasmid DNA using FuGENE6 [15]. Cell num-
ber at the end of experiment was∼5×106. The results normalized to 106 cells per 24 h are
described in the text
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removal [24]. Overall, splicing of heterologous introns occurs with varying effi-
ciency and in some cases introns were completely retained in retroviral vectors
([20] and references therein). However, these experiments were performed using
the LN-type or similar vectors. In order to force package the heterologous in-
trons, the intron-containing genes were also placed by other groups in a reverse
orientation relative to that of viral intron and LTR promoter [10, 23]. This reverse
orientation required transgene expression to be driven by heterologous promoters
in these vectors. However, cryptic poly(A) or splicing signals in the complemen-
tary strand of heterologous intron or transgene in these situations may interfere
with retroviral packaging or transduction [26].
Expression of transgenes from the LTR promoter in MFG vector has some
merit as shown by the use of this backbone for the first-ever report of a successful
gene therapy trial in humans [5]. Furthermore, as discussed above the packaging
of heterologous introns in retroviral RNA is possible. Therefore, we tested the
possibility of enhancing the performance of MFG LTR driven vectors by inclusion
of transgene contained intron as described below.
We previously observed that an internally truncated version of human coag-
ulation factor IX (hFIX) intron I increased hFIX expression by 10–12 fold and
does not contain poly(A) or cryptic splicing signals [14, 26]. Therefore, we hy-
pothesized that in the MFG context it may be possible to achieve packaging of
virions with the viral genomes containing this hFIX intron in the same orienta-
tion as the viral intron, thus further enhancing transgene expression driven by the
LTR promoter. We tested this by MFG vectors with hFIX (cDNA with and with-
out an intron) as a reporter gene (Fig. 1a). MFG retroviral vectors constructed,
MFG/hFIXc and MFG/hFIXm2, contained hFIX cDNA or hFIX minigene (cDNA
with an intron), respectively, and then hFIX expression levels were analyzed in
comparison to those of LN-type vectors, LIXcSN or LIXm2SN (Fig. 1a).
Myoblasts [28] transiently transfected with hFIX minigene vectors, MFG/
hFIXm2 or LIXm2SN, produced 2- or 4-fold higher hFIX than those transfected
with hFIX cDNA containing vectors, MFG/hFIXc or LIXcSN, respectively (Fig.
1b). Similarly, levels of hFIX produced by HepG2 cells transfected with LIXcSN,
LIXm2SN, MFG/hFIXc and MFG/hFIXm2 were 16± 9, 35± 12, 30± 14 and
98± 37 ng/106 cells/24 hours, respectively (Mean± SD, n= 6) (see legend to
Fig. 1b). Enhanced hFIX expression from hFIX minigene containing retroviral
plasmids over those with hFIX cDNA is consistent with previous results obtained
with non-retroviral plasmid vectors [14, 26].
Effects of the hFIX minigene intron on retroviral transduction were then ex-
amined by using retroviral vectors prepared by transient transfection of Phoenix A
retroviral packaging cell line [9, 12]. Relative titers of recombinant viruses were
determined by RNA slot-blot hybridization [19] using hFIX DNA probe. Viral
titers relative to LIXcSN (defined 100) were 102± 30, 129± 46 and 117± 28
(Mean± SEM, n=5) for LIXm2SN, MFG/hFIXc and MFG/hFIXm2, respec-
tively. These results suggested that the hFIX intron does not confer any significant
increase in titer, and all vectors are packaged with near equal efficiency. Primary
mouse myoblasts were then transduced with retroviral supernatant and hFIX ex-
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pression was determined by Enzyme Linked Immunosorbant Assay (ELISA [14]).
Both LIXcSN and LIXm2SN produced hFIX at low levels, agreeing with the pre-
vious results (Fig. 2a) [8, 26, 29]. Surprisingly, LIXcSN expressed up to two-fold
higher hFIX than LIXm2SN (Fig. 2a). Myotubes transduced with MFG/hFIXc
also expressed two-fold higher levels of hFIX compared to MFG/hFIXm2 trans-
duced myotubes (172–191 versus 67–99 ng hFIX/106 cells/24 h) (Fig. 2a). Similar
results were obtained in transduced HepG2 cells, though the hFIX levels produced
were lower than those by myoblasts. HepG2 cells transduced with MFG/hFIXc
expressed hFIX at∼2-fold higher levels than with MFG/hFIXm2 (21 versus
10 ng/106 cells/24 h; n=4). Together, these results suggested that the presence of
hFIX intron in MFG vectors neither contributes to enhancement of viral titer nor
hFIX transgene expression.
In transduced myoblasts, hFIX mRNA levels were in order of MFG/hFIXc>
MFG/hFIXm2>LIXcSN>LIXm2SN (Fig. 2b), which is consistent with the hFIX
protein expression levels (Fig. 2a). The lower hFIX mRNA levels of LIXcSN or
LIXm2SN may be due to the non-MFG retroviral backbone in these constructs and
also in part to the presence of SV-neo (Fig. 1a and 2b, lanes 2 and 3). Importantly,
the ratio of unspliced and spliced transcripts was very similar for MFG/hFIXc or
MFG/hFIXm2, 1.13 and 1.19, respectively (Fig. 2b, lanes 4–6). Thus, splicing
ratios alone cannot explain the differences in hFIX expression level between
MFG/hFIXc and MFG/hFIXm2 vectors.
Since viral RNA is reverse transcribed and integrated into genomic DNA
prior to transgene expression, the state of integrated vector in genomic DNA of
the transduced cells should reflect the status of viral genomic RNA in virions.
When genomic DNA isolated from the transduced myoblasts was subjected to
PCR analysis using primers specific to the U3 region in retroviral LTR and the
second exon of hFIX, MFG/hFIXc transduced myoblasts gave a 1.37-kb band,
as expected (Fig. 2c, lane 8). However, MFG/hFIXm2 transduced myoblasts
did not give the expected 1.67-kb band which represents the intron-retained
form, but instead, gave the 1.37-kb product corresponding to intron-spliced form
(Fig. 2c, lane 9). Nucleotide sequencing of the junction region of hFIX exon 1 and
2 in 1.37-kb PCR products from MFG/hFIXm2 transduced cells indicated that
the splicing of hFIX intron was complete and not aberrant (data not shown). Simi-
larly, genomic DNA from LIXm2SN transduced myoblasts did not have the hFIX
intron sequence (Fig. 2c, lanes 6 and 7). These results suggested that hFIX intron
was not present in the genomic RNA of MFG/hFIXm2 or LIXm2SN viruses that
were used for transduction. However, Northern blot analysis of genomic RNA
prepared from virions concentrated from the retroviral supernatant according to
the method described by Cepko [6] showed reactivity to hFIX intron fragment
hybridization probe (data not shown), Together, these analyses suggested that the
viral RNA with or without the hFIX intron sequence are packaged, but the hFIX
intron containing viral RNA fails to integrate into the genome of the transduced
cells. This suggested that presence of the hFIX intron sequence may possibly
suppress reverse transcription and/or integration steps in the target cells, and only
a small population of MFG/hFIXm2 or LIXm2SN viral RNA, can get integrated,
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c
Fig. 2. aExpression of hFIX from myoblasts and myotubes transduced with recombinant
retroviruses. Transduction of mouse myoblasts was performed by plating the cells at 105
cells/well (6-well plate) to obtain 30% confluency on the next day. Cells were then infected
with 2 ml of viral supernatant in the presence of 8mg/ml polybrene with centrifugation at
1180×g for 30 min at 32◦C using a microplate carrier. The first infection was followed by
additional infections at 10 and 24 h later to obtain virtually 100% transduction. For quantita-
tive determination of hFIX production, 5×105 transduced myoblasts were plated per well of
6-well plates in 2 ml of growth medium (DMEM supplemented with Vitamin K1 (10mg/ml),
20% BaSO4-treated FBS and 0.5% CEE) for 1 day, followed by changing to differentia-
tion medium (DMEM/Vitamin K1/2.5% BaSO4-treated FBS) and incubation for 3 additional
days. The medium was then switched to growth medium and cells were incubated for 2 more
days. The medium was collected and replenished every 24 h and assayed for hFIX by ELISA.
Myoblasts were>90% confluent at the start of differentiation. On day 2, cell numbers were
counted in two wells and used for normalizing results to per 106 cells. Decline in expres-
sion of hFIX from MFG/hFIXm2 transduced cells on day 6 is due to cell release from the
plates as previously observed [26].b Northern blot analysis. Northern blot analysis was done
as previously described [14] using 10mg total RNA prepared from transduced myoblasts
and 1% agarose/formaldehyde gel. The32P labeled hFIX minigene DNA was used as the
hybridization probe. As an internal control, 1.1-kbEcoRI-Hind III cDNA fragment of cel-
lular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (IMAGE. consortium clone ID
360840; American Type Culture Collection) was used. Relative ratios of GAPDH mRNA
bands in this experiment were 2.11, 1.85, 1.84 and 1.0 for LIXcSN, LIXm2SN, MFG/hFIXc
and MFG/hFIXm2 transduced myoblasts, respectively. Arrows on the right indicate pos-
sible spliced and unspliced transcripts from myoblasts transduced with MFG/hFIXc and
MFG/hFIXm2 viruses (4–6) as judged from expected sizes (shown in Fig. 1a) and were used
for calculating unspliced/spliced RNA ratios (see text). This ratio could not be determined
for LIXcSN and LIXm2SN since the spliced transcripts were not clearly visible (2 and3).
Higher molecular size RNA bands, also seen previously [26], in all lanes are also possibly
full-length transcripts that are migrating anamolously, due to unknown mechanisms.1 RNA
from uninfected myoblasts.2–5 RNA from myoblasts infected with LIXcSN, LIXm2SN,
MFG/hFIXc, and MFG/hFIXm2, respectively.6 is a shorter exposure of4. The histogram
underneath represents total hFIX RNA amounts for2–5, expressed relative to LIXcSN, which
were quantified with the STORM phosphorimager (Molecular Dynamics). The arbitrary RNA
units in the histogram have been corrected for total RNA loaded per lane based on the mea-
sured values of GAPDH mRNA.c PCR analysis of genomic DNA isolated from transduced
myoblasts. Aliquots of genomic DNA (5mg) were subjected to PCR using 0.4mM each
of forward primer in retroviral promoter region (5′-TCTGTGTGATTGACTACCCG-3′) and
reverse primer in hFIX exon 2 (5′-GGCCGATTCAGAATTTTGTTG-3′) in the presence of
0.2 mM each of dATP, dCTP and dTTP, and 0.15 mM of dGTP, 0.05 mM of 7-deaza-dGTP,
2.5% (v/v) formamide and AmpliTaq DNA polymerase (Roche). PCR was composed of an
initial 3 min denaturation at 94◦C, followed by 25 cycles of 1 min denaturation at 94◦C,
1 min annealing at 52◦C and extension at 72◦C for 1 min. One-tenth of the reaction products
were resolved on 0.7% agarose gel and stained with ethidium bromide.1 1 Kb Plus DNA
Ladder (Gibco-BRL).2–5 PCR products of plasmid DNAs as labeled.6–9 PCR products
of genomic DNAs isolated from myoblasts transduced with viruses as indicated. Arrows
indicate the expected products, in sizes shown
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contributing towards transgene expression. This proposed mechanism may also
explain why the overall levels of hFIX mRNA are significantly higher in MFG/hFIXc
or LIXcSN transduced cells than MFG/hFIXm2 or LIXm2SN transduced cells,
respectively.
As shown for factor VIII, some coding sequence of the transgene can grossly
alter retroviral titer and transgene expression [16]. Furthermore, the neomycin
resistance gene has been shown to exert negative effects on expression of the
other transgene in the same retroviral vector in a multi-cystronic organization [3].
Unlike factor VIII, we do not observe any reduction in the titer of MFG/hFIXm2
vectors, suggesting a possibility that the hFIX intron sequence may exert a nega-
tive control at a post-packaging, but pre-integration step(s) in target cells [25]. A
short polypurine tract near 3′-end of a retroviral genome is involved in plus-strand
DNA synthesis during retroviral replication. Although BLAST [1] search of the
0.3-kb hFIX intron did not reveal any homology to retroviral sequences, the hFIX
intron sequence has several stretches of A and G nucleotides, suggesting a possi-
bility that the hFIX intron may interfere in a dominant negative fashion with the
wild-type polypurine tract during reverse transcription of the vector RNA prior
to integration in transduced cells [22]. This possibility will be further tested.
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In summary, our results indicate that in the MFG retroviral context, the hFIX
minigene intron has a negative influence on transgene expression, presumably
due to the interference effects of the second intron on retroviral generation and
transduction processes.
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